Pfizer and its German partner BioNTech said on Friday they filed an application to the FDA for a full approval of their Omicron-adapted COVID-19 vaccine.
Maternal vaccination with two doses of the mRNA COVID-19 vaccine was 95% effective against infant infection from the Delta variant, and 45% effective against infant infection from the Omicron variant.
Sinopharm said on Friday its biotech unit has received regulatory approval for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant.
The fast-spreading Omicron subvariant XBB.1.5 is estimated to account for 43% of the COVID-19 cases in the United States for the week ended Jan. 14, data from the CDC showed.